Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.69 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.69 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202916 | 0.84 | KEAP1 (0.75) | KEAP1NFE2L2CYP2A6EPHX1CA2 | |
| SCHEMBL6821884 | 0.82 | KEAP1 (0.77) | KEAP1NFE2L2CYP2A6EPHX1CA2 | |
| SCHEMBL1520041 | 0.82 | KEAP1 (1.00) | KEAP1NFE2L2CYP2A6EPHX1CA2 | |
| SCHEMBL12359753 | 0.81 | KEAP1 (0.75) | KEAP1NFE2L2CYP2A6EPHX1CA2 | |
| Hydrochloric Acid SCHEMBL6821885 | 0.81 | KEAP1 (0.97) | KEAP1NFE2L2CYP2A6EPHX1CA2 | |
| SCHEMBL2251923 | 0.79 | KEAP1 (0.73) | KEAP1NFE2L2CYP2A6EPHX1CA2 | |
| SCHEMBL13995272 | 0.79 | CYP2A6 (0.56) | CYP2A6CA2MAPTSMN1; SMN2 | |
| SCHEMBL838775 | 0.79 | KEAP1 (0.63) | KEAP1NFE2L2CYP2A6EPHX1CA2 | |
| SCHEMBL21411562 | 0.79 | KEAP1 (0.63) | KEAP1NFE2L2CYP2A6EPHX1CA2 | |
| SCHEMBL7116432 | 0.77 | KEAP1 (0.69) | KEAP1NFE2L2CYP2A6EPHX1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465798-B2 | Methods and compositions for selectin inhibition | WYETH (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080125454-A1 | preventing selectin-mediated leukocyte adhesion to the vascular endothelium; 2-(4-Chloro-phenyl)-3-hydroxy-benzo[h]quinoline-4-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-h]quinoline-6-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-9-aza-cyclopenta[a]naphthale | WYETH (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125454-A1 | preventing selectin-mediated leukocyte adhesion to the vascular endothelium; 2-(4-Chloro-phenyl)-3-hydroxy-benzo[h]quinoline-4-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-h]quinoline-6-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-9-aza-cyclopenta[a]naphthale | SELL, VCAM1, SELE | KEAP1 431/4885NFE2L2 535/4885CYP2A6 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.